{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:14Z","timestamp":1789052414975,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtha.2025.02.038","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:26:47Z","timestamp":1741346807000},"page":"2178-2189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world evaluation of a novel automated method for measuring ADAMTS-13 activity using the Ceveron s100 analyzer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0151-337X","authenticated-orcid":false,"given":"B\u00e9rang\u00e8re S.","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Deniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Doinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Brouillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.038_bib1","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib2","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.02.038_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jth.12221","article-title":"Structure-function and regulation of ADAMTS-13 protease","volume":"11","author":"Zheng","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"Upshaw","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.02.038_bib7","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib8","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib12","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100534","article-title":"OC 14.4 Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: interim analysis from phase 3B continuation study","volume":"7","author":"Coppo","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.02.038_bib18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.038_bib19","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib20","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib23","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.038_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ijlh.13295","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13","volume":"42","author":"Mackie","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jth.12881","article-title":"Establishment of the WHO 1st International Standard ADAMTS13, plasma (12\/252): communication from the SSC of the ISTH","volume":"13","author":"Hubbard","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1055\/s-0037-1614780","article-title":"Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)","volume":"82","author":"Gerritsen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00277-002-0502-3","article-title":"Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13)","volume":"81","author":"B\u00f6hm","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1160\/TH13-05-0393","article-title":"Evaluation of a commercial assay for ADAMTS13 activity measurement","volume":"110","author":"Thouzeau","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.thromres.2014.09.006","article-title":"Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement","volume":"134","author":"Joly","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.038_bib30","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1055\/s-0037-1614779","article-title":"Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF","volume":"82","author":"Obert","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1538-7836.2006.01758.x","article-title":"A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption\/ionization time-of-flight (SELDI-TOF)-mass spectrometry","volume":"4","author":"Jin","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib34","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.02.038_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.02.038_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1055\/s-0038-1641151","article-title":"Evaluation of the fully automated HemosIL Acustar ADAMTS13 activity assay","volume":"118","author":"Favresse","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib38","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14815","article-title":"A multi-center evaluation of TECHNOSCREEN\u00ae ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13","volume":"18","author":"Moore","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102171","article-title":"Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay","volume":"7","author":"Bonnez","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.15219","article-title":"The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura","volume":"184","author":"Thomas","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib41","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity","volume":"119","author":"Valsecchi","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11239-020-02086-8","article-title":"Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study","volume":"50","author":"Stratmann","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.02.038_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/rth2.12461","article-title":"Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay","volume":"5","author":"Beranger","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ijlh.13414","article-title":"Multicentric evaluation of the new HemosIL Acustar\u00ae chemiluminescence ADAMTS13 activity assay","volume":"43","author":"Pascual","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib47","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/ijlh.14090","article-title":"Evaluation of two fully automated ADAMTS13 activity assays in comparison to manual FRET assay","volume":"45","author":"Irsara","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.02.038_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ijlh.13936","article-title":"Implementation of the new EUR IVD regulation and relation with ISO15189 accreditation: guidance is urgently required for haemostasis testing","volume":"44","author":"Testa","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib50","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1055\/s-0038-1673686","article-title":"ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the French cohort of Upshaw-Schulman syndrome","volume":"118","author":"Joly","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib51","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","article-title":"Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies","volume":"5","author":"Meyer","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/ijlh.14077","article-title":"A multicenter evaluation of the Technoscreen ADAMTS13 activity semi-quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion","volume":"45","author":"Stephenson","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.038_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.038_bib55","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2023-188996","article-title":"Recombinant ADAMTS13 for the treatment of acute TTP events in patients with congenital thrombotic thrombocytopenic purpura: results from the phase 3 randomized, controlled, crossover study and the phase 3b continuation study","volume":"142","author":"Scully","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.038_bib56","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/jcm13154462","article-title":"Practical considerations for the use of the Rapid AcuStar\u00ae ADAMTS13 activity assay in the diagnosis of acute thrombotic thrombocytopenic purpura (TTP)","volume":"13","author":"Yong","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib57","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.3390\/jcm12196169","article-title":"ADAMTS13 and non-ADAMTS13 biomarkers in immune-mediated thrombotic thrombocytopenic purpura","volume":"12","author":"Bonnez","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.02.038_bib58","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.jtha.2024.03.012","article-title":"Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation","volume":"22","author":"Bonnez","year":"2024","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:32:10Z","timestamp":1778139130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1538783625001370"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.038","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of a novel automated method for measuring ADAMTS-13 activity using the Ceveron s100 analyzer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}